LifeStance Health Group, Inc. is an outpatient mental health provider operating a tech-enabled platform for in-person and virtual care delivery. The company employs licensed clinicians, including psychiatrists, psychologists, and therapists, to provide a multidisciplinary suite of services such as psychiatric evaluations, medication management, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. LifeStance serves patients across 33 U.S. states through its network of centers and an online delivery platform. The company maintains in-network relationships with multiple national payors and partners with primary care and specialist physicians to facilitate referrals and integrated care. Its business model focuses on reducing administrative burdens for clinicians while expanding patient access to affordable mental healthcare.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Care Facilities Homepage lifestance.com
Sector Healthcare IR page lifestance.com
Tags
outpatient mental health, psychiatry, psychotherapy, telehealth, psychological testing, behavioral health, integrated care
Press page lifestance.com/media-center

Metrics

Valuation  
Market cap $ 5.441B
Market cap (USD) $ 5.441B
P/E 75.66
PEG —
P/BV 3.65
P/S 3.24
P/OCF 23.90
P/FCF 30.35
Dividend yield —
Turnover / mcap —
Returns  
ROE 0.65%
ROI 0.54%
ROIC 1.0%
Profit margin 0.68%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 18.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 1.424B 1.251B 1.056B 859.542M 1.445M
Net profit 9.663M -57.443M -186.262M -215.564M -307.197M
Free cash flow 110.026M 85.694M -57.404M -26.466M -85.072M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 7.04 7.37 7.83 4.94 9.52
Price performance 12m -0.04 -0.06 0.59 -0.48 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 43.7M 76.1M 101M 125M 132M 95.7M
↳ YoY growth +74.1% +32.6% +24.3% +5.1% -27.4%
↳ 5y CAGR +17.0%
Borrowings, current (USD) — — 3.74M 1.32M 2.35M 2.93M 7.25M 14.5M
Borrowings, non-current (USD) — — 363M 157M 225M 280M 280M 266M
Lease liabilities (USD) — — — 0.00 251M 228M 198M 194M
Cash and deposits (USD) 11.3M 3.48M 18.8M 148M 109M 78.8M 155M 249M
Intangible assets (USD) — — 333M 300M 263M 221M 191M 178M
Right-of-use assets (USD) — — — 0.00 199M 171M 148M 150M
Net debt (borrowings + leases - cash) (USD) — — 347M 10.7M 370M 432M 331M 226M
Cash flow detail
Operating cash flow (USD) — 17M — 9.42M 52.8M -16.9M 107M 146M
Purchases of property, plant and equipment (USD) — -14.3M — -94.5M -79.3M -40.5M -21.6M -36.1M
Change in receivables (cash effect) (USD) — -5.76M — -24.2M -21.7M -24.2M -6.4M 36.1M
Change in payables (cash effect) (USD) — 2.54M — 623,000 7.67M -5.61M 501,000 -1.56M
Interest paid (cash effect) (USD) — -4.58M — -22.4M -14.4M -21M -25M -17.8M
Income taxes paid (cash effect) (USD) — -254,000 — -1.09M -2.24M -80,000 -57,000 -1.57M
Share-based compensation (USD) — 54,000 — 259M 187M 99.4M 76.2M 74.7M
Operating cash flow before change in receivables (USD) — 22.8M — 33.6M 74.5M 7.29M 114M 110M
Free cash flow (OCF - PPE - intangibles) (USD) — 2.73M — -85.1M -26.5M -57.4M 85.7M 110M
Income detail
Total comprehensive income (USD) — 5.67M — -307M -212M -187M -58.8M 8.73M
Comprehensive income to owners (USD) — 5.67M — -307M -212M -187M -58.8M 8.73M
Reported Mar 17, 2022 Mar 17, 2022 Aug 12, 2021 Mar 9, 2023 Mar 9, 2023 Feb 28, 2024 Feb 27, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

LifeStance Health Group, Inc. — Other Events Bull 0 Bear 4 Routine

On November 9, 2026, LifeStance Health Group, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) by and among the Company, Barclays Capital Inc. (“Barclays”), J.P. Morgan Securities LLC (together with Barclays, the “Underwriters”), and the selling stockholders named in Schedule II thereto (the “Selling Stockholders”), relating to the underwritten offering of 45,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), pursuant to the Company’s registration statement on Form S-3 (File No. 333-279585), filed on May 21, 2024 (the “Registration Statement”). In addition, pursuant to the Underwriting Agreement, the Company has purchased from the Underwriters 2,000,000 Shares sold by the Selling Stockholders to the Underwriters, at a price per share equal to the price per share paid by the Underwriters to the Selling Stockholders. The Underwriters did not receive any compensation for the shares of the Common Stock repurchased by the Company. All of the Shares were sold by the Selling Stockholders. The Company did not receive any proceeds from the offering.

SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2026.

(All results compared to prior-year comparative period, unless otherwise noted) Q3 2026 Highlights and FY 2026 Outlook

  • Revenue of $455.9 million increased 25% compared to revenue of $363.8 million

  • Clinician base increased 11% to 8,863 clinicians, a sequential net increase of 321 in the third quarter

  • Third quarter visit volumes increased 17% to 2.7 million

  • Net income of $22.4 million compared to net income of $1.1 million

  • Adjusted EBITDA of $68.4 million compared to Adjusted EBITDA of $40.2 million

  • Net cash provided by operations of $37.0 million in the third quarter

  • Free Cash Flow generation of $22.4 million in the third quarter

  • For full year 2026, raising revenue expectations to $1.741 billion to $1.761 billion, Center Margin expectations to $599 million to $613 million, and Adjusted EBITDA expectations to $242 million to $250 million

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations,” said Dave Bourdon, CEO of LifeStance. “The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence. At the same time, the investments we are making in our platform, including the implementation of our new EHR, are positioning LifeStance for continued success and scale over the long term.”

| Financial Highlights | | | | | | | | | |

| | | Q3 2026 | | | Q3 2025 | | | Y/Y | |

| (in millions) | | | | | | | | | |

| Total revenue | | $ | 455.9 | | | $ | 363.8 | | | | 25 | % |

| Income from operations | | | 33.1 | | | | 7.4 | | | NM | |

| Center Margin | | | 161.4 | | | | 116.6 | | | | 38 | % |

| Net income | | | 22.4 | | | | 1.1 | | | NM | |

| Adjusted EBITDA | | | 68.4 | | | | 40.2 | | | | 70 | % |

| As % of Total revenue: | | | | | | | | | |

| Income from operations | | | 7.3 | % | | | 2.0 | % | | | |

| Center Margin | | | 35.4 | % | | | 32.0 | % | | | |

| Net income | | | 4.9 | % | | | 0.3 | % | | | |

| Adjusted EBITDA | | | 15.0 | % | | | 11.1 | % | | | |


NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

  • Revenue grew 25% to $455.9 million. Revenue growth in the third quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

  • Income from operations was $33.1 million and net income was $22.4 million.

  • Center Margin grew 38% to $161.4 million, or 35.4% of total revenue.

  • Adjusted EBITDA increased 70% to $68.4 million, or 15.0% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the third quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the nine months ended September 30, 2026, LifeStance generated $170.0 million of cash flow from operations, including $37.0 million during the third quarter of 2026. The Company ended the third quarter with cash and cash equivalents of $218.8 million and net long-term debt of $255.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

  • The Company is raising full year revenue to $1.741 billion to $1.761 billion, Center Margin to $599 million to $613 million, and Adjusted EBITDA to $242 million to $250 million.

  • For the fourth quarter of 2026, the Company expects total revenue of $446 million to $466 million, Center Margin of $149 million to $163 million, and Adjusted EBITDA of $56 million to $64 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, November 5, 2026 at 8:30 a.m. Eastern Time to discuss the third quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 3056663 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,800 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 35 states and more than 575 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and fourth quarter guidance and management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income (loss) or income from operations.

Center Margin and Adjusted EBITDA anticipated for the fourth quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking fourth quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

| Consolidated Financial Information and Reconciliations |

| |

| CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands, except for par value) |

| |

| | | September 30, 2026 | | | December 31, 2025 | |

| CURRENT ASSETS | | | | | | |

| Cash and cash equivalents | | $ | 218,818 | | | $ | 248,642 | |

| Patient accounts receivable, net | | | 120,940 | | | | 95,710 | |

| Prepaid expenses and other current assets | | | 37,021 | | | | 71,848 | |

| Total current assets | | | 376,779 | | | | 416,200 | |

| NONCURRENT ASSETS | | | | | | |

| Property and equipment, net | | | 166,428 | | | | 161,583 | |

| Right-of-use assets | | | 162,395 | | | | 149,720 | |

| Intangible assets, net | | | 170,041 | | | | 177,665 | |

| Goodwill | | | 1,305,389 | | | | 1,293,346 | |

| Other noncurrent assets | | | 5,251 | | | | 5,419 | |

| Total noncurrent assets | | | 1,809,504 | | | | 1,787,733 | |

| Total assets | | $ | 2,186,283 | | | $ | 2,203,933 | |

| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |

| CURRENT LIABILITIES | | | | | | |

| Accounts payable | | $ | 5,502 | | | $ | 6,122 | |

| Accrued payroll expenses | | | 129,848 | | | | 143,327 | |

| Other accrued expenses | | | 60,099 | | | | 42,187 | |

| Operating lease liabilities, current | | | 45,039 | | | | 45,544 | |

| Other current liabilities | | | 20,641 | | | | 14,782 | |

| Total current liabilities | | | 261,129 | | | | 251,962 | |

| NONCURRENT LIABILITIES | | | | | | |

| Long-term debt, net | | | 255,524 | | | | 265,927 | |

| Operating lease liabilities, noncurrent | | | 160,458 | | | | 148,553 | |

| Deferred tax liability, net | | | 16,408 | | | | 16,408 | |

| Other noncurrent liabilities | | | 373 | | | | 68 | |

| Total noncurrent liabilities | | | 432,763 | | | | 430,956 | |

| Total liabilities | | $ | 693,892 | | | $ | 682,918 | |

| COMMITMENTS AND CONTINGENCIES | | | | | | |

| STOCKHOLDERS’ EQUITY | | | | | | |

| Preferred stock – par value $0.01 per share; 25,000 shares authorized as of September 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | | | — | | | | — | |

| Common stock – par value $0.01 per share; 800,000 shares authorized as of September 30, 2026 and December 31, 2025; 380,191 and 388,318 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | | | 3,802 | | | | 3,883 | |

| Additional paid-in capital | | | 2,236,975 | | | | 2,325,758 | |

| Accumulated deficit | | | (748,386 | ) | | | (808,626 | ) |

| Total stockholders' equity | | | 1,492,391 | | | | 1,521,015 | |

| Total liabilities and stockholders’ equity | | $ | 2,186,283 | | | $ | 2,203,933 | |

| | | | | | | | | |

| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) (In thousands, except per share amounts) |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| TOTAL REVENUE | | $ | 455,864 | | | $ | 363,809 | | | $ | 1,294,694 | | | $ | 1,042,090 | |

| OPERATING EXPENSES | | | | | | | | | | | | |

| Center costs, excluding depreciation and amortization shown separately below | | | 294,462 | | | | 247,227 | | | | 844,319 | | | | 707,286 | |

| General and administrative expenses | | | 113,389 | | | | 95,615 | | | | 321,858 | | | | 287,421 | |

| Depreciation and amortization | | | 14,936 | | | | 13,557 | | | | 42,503 | | | | 41,319 | |

| Total operating expenses | | $ | 422,787 | | | $ | 356,399 | | | $ | 1,208,680 | | | $ | 1,036,026 | |

| INCOME FROM OPERATIONS | | $ | 33,077 | | | $ | 7,410 | | | $ | 86,014 | | | $ | 6,064 | |

| OTHER EXPENSE | | | | | | | | | | | | |

| Loss on remeasurement of contingent consideration | | | (2,339 | ) | | | — | | | | (2,370 | ) | | | — | |

| Transaction costs | | | (510 | ) | | | — | | | | (1,499 | ) | | | — | |

| Interest expense, net | | | (2,491 | ) | | | (2,814 | ) | | | (6,916 | ) | | | (8,787 | ) |

| Other expense | | | (334 | ) | | | (24 | ) | | | (609 | ) | | | (117 | ) |

| Total other expense | | $ | (5,674 | ) | | $ | (2,838 | ) | | $ | (11,394 | ) | | $ | (8,904 | ) |

| INCOME (LOSS) BEFORE INCOME TAXES | | | 27,403 | | | | 4,572 | | | | 74,620 | | | | (2,840 | ) |

| INCOME TAX (PROVISION) BENEFIT | | | (5,018 | ) | | | (3,495 | ) | | | (14,380 | ) | | | 835 | |

| NET INCOME (LOSS) | | $ | 22,385 | | | $ | 1,077 | | | $ | 60,240 | | | $ | (2,005 | ) |

| EARNINGS (LOSS) PER SHARE | | | | | | | | | | | | |

| Basic | | | 0.06 | | | | 0.00 | | | | 0.16 | | | | (0.01 | ) |

| Diluted | | | 0.06 | | | | 0.00 | | | | 0.15 | | | | (0.01 | ) |

| Weighted-average shares outstanding | | | | | | | | | | | | |

| Basic | | | 381,214 | | | | 386,963 | | | | 383,976 | | | | 385,672 | |

| Diluted | | | 391,223 | | | | 388,895 | | | | 391,180 | | | | 385,672 | |

| | | | | | | | | | | | | |

| NET INCOME (LOSS) | | $ | 22,385 | | | $ | 1,077 | | | $ | 60,240 | | | $ | (2,005 | ) |

| OTHER COMPREHENSIVE LOSS | | | | | | | | | | | | |

| Unrealized losses on cash flow hedge, net of tax | | | — | | | | (345 | ) | | | — | | | | (929 | ) |

| COMPREHENSIVE INCOME (LOSS) | | $ | 22,385 | | | $ | 732 | | | $ | 60,240 | | | $ | (2,934 | ) |

| | | | | | | | | | | | | | | | | |

| CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (In thousands) | |

| | | | |

| | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | |

| CASH FLOWS FROM OPERATING ACTIVITIES | | | | | | |

| Net income (loss) | | $ | 60,240 | | | $ | (2,005 | ) |

| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | | | | | | |

| Depreciation and amortization | | | 42,503 | | | | 41,319 | |

| Non-cash operating lease costs | | | 32,694 | | | | 31,265 | |

| Stock-based compensation | | | 53,117 | | | | 57,997 | |

| Amortization of discount and debt issue costs | | | 758 | | | | 762 | |

| Other, net | | | 4,356 | | | | 1,440 | |

| Change in operating assets and liabilities, net of businesses acquired: | | | | | | |

| Patient accounts receivable, net | | | (24,381 | ) | | | 10,729 | |

| Prepaid expenses and other current assets | | | 33,546 | | | | (10,410 | ) |

| Accounts payable | | | (513 | ) | | | 2,868 | |

| Accrued payroll expenses | | | (14,146 | ) | | | (3,689 | ) |

| Operating lease liabilities | | | (34,116 | ) | | | (35,829 | ) |

| Other accrued expenses | | | 15,979 | | | | (5,856 | ) |

| Net cash provided by operating activities | | $ | 170,037 | | | $ | 88,591 | |

| CASH FLOWS FROM INVESTING ACTIVITIES | | | | | | |

| Purchases of property and equipment | | | (37,415 | ) | | | (25,214 | ) |

| Acquisitions of businesses, net of cash acquired | | | (9,590 | ) | | | — | |

| Net cash used in investing activities | | $ | (47,005 | ) | | $ | (25,214 | ) |

| CASH FLOWS FROM FINANCING ACTIVITIES | | | | | | |

| Payments of long-term debt | | | (10,875 | ) | | | (5,438 | ) |

| Taxes related to net share settlement of equity awards | | | (24,919 | ) | | | (8,607 | ) |

| Proceeds from the exercise of stock options | | | 5,368 | | | | — | |

| Repurchases of common stock | | | (122,430 | ) | | | — | |

| Net cash used in financing activities | | $ | (152,856 | ) | | $ | (14,045 | ) |

| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | | | (29,824 | ) | | | 49,332 | |

| Cash and cash equivalents - beginning of period | | | 248,642 | | | | 154,571 | |

| CASH AND CASH EQUIVALENTS – END OF PERIOD | | $ | 218,818 | | | $ | 203,903 | |

| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | | | |

| Cash paid for interest, net | | $ | 12,298 | | | $ | 13,253 | |

| Cash paid for taxes, net of refunds | | $ | 1,294 | | | $ | 1,564 | |

| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES | | | | | | |

| Contingent consideration incurred in acquisitions of businesses | | $ | 3,983 | | | $ | — | |

| Acquisition of property and equipment included in liabilities | | $ | 4,546 | | | $ | 4,484 | |

| | | | | | | | | |

| RECONCILIATION OFINCOMEFROM OPERATIONS TO CENTER MARGIN | |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| (in thousands) | | | | | | | | | | | | |

| Income from operations | | $ | 33,077 | | | $ | 7,410 | | | $ | 86,014 | | | $ | 6,064 | |

| Adjusted for: | | | | | | | | | | | | |

| Depreciation and amortization | | | 14,936 | | | | 13,557 | | | | 42,503 | | | | 41,319 | |

| General and administrative expenses(1) | | | 113,389 | | | | 95,615 | | | | 321,858 | | | | 287,421 | |

| Center Margin | | $ | 161,402 | | | $ | 116,582 | | | $ | 450,375 | | | $ | 334,804 | |

| (1) | Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees. |

| | |

| **RECONCILIATION OF NET****INCOME (LOSS)**TO ADJUSTED EBITDA |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| (in thousands) | | | | | | | | | | | | |

| Net income (loss) | | $ | 22,385 | | | $ | 1,077 | | | $ | 60,240 | | | $ | (2,005 | ) |

| Adjusted for: | | | | | | | | | | | | |

| Interest expense, net | | | 2,491 | | | | 2,814 | | | | 6,916 | | | | 8,787 | |

| Depreciation and amortization | | | 14,936 | | | | 13,557 | | | | 42,503 | | | | 41,319 | |

| Income tax provision (benefit) | | | 5,018 | | | | 3,495 | | | | 14,380 | | | | (835 | ) |

| Loss on remeasurement of contingent consideration | | | 2,339 | | | | — | | | | 2,370 | | | | — | |

| Stock-based compensation expense | | | 18,168 | | | | 18,297 | | | | 53,117 | | | | 57,997 | |

| Loss on disposal of assets | | | 334 | | | | 24 | | | | 609 | | | | 117 | |

| Transaction costs(1) | | | 510 | | | | — | | | | 1,499 | | | | — | |

| Executive transition costs | | | — | | | | 577 | | | | — | | | | 1,296 | |

| Litigation costs(2) | | | 34 | | | | (70 | ) | | | (94 | ) | | | 1,088 | |

| Strategic initiatives(3) | | | 1,741 | | | | — | | | | 2,738 | | | | — | |

| Real estate optimization and restructuring charges(4) | | | (27 | ) | | | (6 | ) | | | (38 | ) | | | (103 | ) |

| Amortization of cloud-based software implementation costs(5) | | | 428 | | | | 444 | | | | 1,269 | | | | 1,199 | |

| Adjusted EBITDA | | $ | 68,357 | | | $ | 40,209 | | | $ | 185,509 | | | $ | 108,860 | |

| (1) | Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offerings of shares of our common stock by certain selling stockholders completed in the three and nine months ended September 30, 2026. |

| (2) | Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three and nine months ended September 30, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three and nine months ended September 30, 2025, a compensation model class action litigation. |

| (3) | Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. |

| (4) | Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three and nine months ended September 30, 2026 and 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023. |

| (5) | Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income (loss). |

| | |

Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 [email protected]

IR Tools

In the news release, LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows, issued 29-Oct-2026 by LifeStance Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows

LifeStance Expands Specialty Services, Increasing Access to Esketamine (Spravato) and Transcranial Magnetic Stimulation (TMS) Across the U.S.

SCOTTSDALE, Ariz., Oct. 29, 2026 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental healthcare, is expanding access to two specialty services for treatment-resistant depression – esketamine1 (Spravato) and transcranial magnetic stimulation2 (TMS) – as separate analyses show meaningful reductions in depression symptoms and suicidal ideation among patients receiving each treatment.

LifeStance Health Logo

Patients with treatment-resistant depression experience persistent depressive symptoms and increased risk of suicidality despite adequate trials of conventional antidepressant medications and/or evidence-based psychotherapies. On average, these patients spend 571 days in a depressive episode and experience significant impacts to daily functioning and quality of life.

LifeStance analyzed outcomes for patients with treatment-resistant depression receiving either esketamine or TMS. In both analyses, their progress was evaluated using the Patient Health Questionnaire (PHQ-9), which measures depression symptom severity over time.

For LifeStance patients receiving esketamine:

  • 74% of patients experienced a clinically meaningful3 reduction in depression severity after 12 weeks of treatment.

  • Before treatment, 13% of patients reported suicidal ideation nearly every day. Following treatment, that figure decreased to 2%, reflecting an 85% reduction.

  • The analysis included 258 LifeStance patients.

For LifeStance patients receiving TMS:

  • 61% of patients experienced a clinically meaningful reduction in depression severity after completing at least 30 treatment sessions.

  • Before treatment, 13% of patients reported suicidal ideation nearly every day. Following treatment, that figure decreased to 6%, reflecting a 50% reduction.

  • The analysis included 355 LifeStance patients.

These observational results describe the patients included in the analyses and do not guarantee individual outcomes. However, the data supports that these evidence-based treatment options may benefit appropriate patients – even those who have struggled to find sufficient relief through previous treatment.

The need for specialty treatment options like esketamine and TMS is significant. In the U.S., treatment-resistant depression affects about 30% of people diagnosed with major depressive disorder, or 2.8 million people, according to a study published in The Journal of Clinical Psychiatry. LifeStance estimates approximately 139,000 of its adult patients experienced treatment-resistant depression in the past year, representing a substantial population that may benefit from additional evidence-based options when conventional treatments have not provided sufficient relief. This is equivalent to 28% of all LifeStance patients with depression and roughly 14% of the more than one million total patients the organization serves annually.

"For patients with treatment-resistant depression, not finding relief from previous treatments does not mean they are out of options," said Dr. Stephanie Eken, Chief Medical Officer, LifeStance Health. "The improvements we're seeing at LifeStance with esketamine and TMS offer new hope for patients who have continued to struggle, including those experiencing the most severe symptoms and suicidal ideation. Too many patients are still waiting for relief when there are effective, evidence-based treatment options that may help. We're committed to expanding access to these specialty services so more patients have the opportunity to receive the most effective treatments tailored to their individual clinical needs."

LifeStance's complete esketamine and TMS outcomes reports are available at LifeStance.com.

As part of its commitment to clinical excellence, LifeStance publishes clinical outcomes data regularly, using measurement-based care to track patient progress throughout treatment. These analyses follow earlier 2026 reports on depression and anxiety treatment outcomes among more than 180,000 patients and outcomes across generations and geographic regions.

If you or someone you know is in crisis, please call, text or chat with the Suicide and Crisis Lifeline at 988, or contact the Crisis Text Line by texting TALK to 741741.

About LifeStance Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 8,500 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 35 states and more than 550 centers.

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: our plans with respect to specialty services and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as "may," "will," "should," "could," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "seek" and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements.

1Esketamine (Spravato) is an FDA-approved nasal spray for adults with treatment-resistant depression, used with or without an antidepressant. It is administered in-person under clinician supervision, typically twice weekly for four weeks, followed by weekly or every-other-week maintenance treatment. 2TMS is an FDA-approved, non-invasive treatment for individuals with treatment-resistant depression. It is a form of brain stimulation that targets areas involved in mood regulation, often used after patients have tried multiple antidepressants and psychotherapy without sufficient relief. 3Clinically meaningful improvement is defined as a PHQ-9 severity score reduction of five or more points.

Correction: An earlier version of this release required an update to remove a paragraph.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lifestance-patients-with-treatment-resistant-depression-see-clinically-meaningful-improvement-in-symptoms-after-esketamine-or-tms-treatment-new-data-shows-302922942.html

SOURCE LifeStance Health

[email protected]

IR Tools

Prompts

LifeStance Health Group, Inc. (ticker LFST), listed in United States.

ETFs Holding LifeStance Health Group, Inc.

ETF Weight in ETF Shares Market value As of
FMED 3.00% 124,900 $ 1.544M Aug 31, 2026
SAWS 1.21% 9,012 $ 94.446K Jul 31, 2026
SMIZ 0.45% 99,591 $ 1.231M Aug 31, 2026
OASC 0.44% 33,447 $ 413.405K Aug 31, 2026
AFSM 0.38% 38,551 $ 558.218K Nov 16, 2026
EHLS 0.32% 12,070 $ 174.774K Nov 17, 2026
LGHT 0.28% 645 $ 6,907.95 Jun 30, 2026
MMSC 0.22% 7,447 $ 107.833K Nov 16, 2026
FFSM 0.22% 308,404 $ 3.232M Jul 31, 2026
SEIS 0.19% 100,495 $ 1.076M Jun 30, 2026
FSML 0.13% 14,643 $ 156.827K Jun 30, 2026
RESM 0.12% 401 $ 4,294.71 Jun 30, 2026
DFAS 0.11% 2,635,638 $ 37.294M Nov 12, 2026
PSC 0.09% 202,384 $ 2.168M Jun 30, 2026
SMDX 0.08% 7,242 $ 104.864K Nov 17, 2026
VFMO 0.06% 92,318 $ 1.141M Aug 31, 2026
DFAT 0.05% 1,077,550 $ 15.247M Nov 12, 2026
DXUV 0.04% 196,311 $ 2.778M Nov 12, 2026
DFAC 0.02% 1,269,054 $ 17.957M Nov 12, 2026
DFSU 0.02% 34,343 $ 485.953K Nov 12, 2026
DFAU 0.01% 92,331 $ 1.306M Nov 12, 2026
DCOR 0.01% 317,064 $ 4.486M Nov 12, 2026
MSSM 0.01% 3,508 $ 43.359K Aug 31, 2026
DFUS 0.01% 81,135 $ 1.148M Nov 12, 2026
EBI 0.00% 242 $ 2,991.12 Aug 31, 2026
DFUV 0.00% 3,126 $ 44.233K Nov 12, 2026
SHRT 0.00% 30 $ 434.40 Nov 17, 2026